<div id="readability-page-1">02:36 PM EST, 01/20/2026 (MT Newswires) -- Ardelyx ( ARDX ) may be acquired by Zydus Life, a pharmaceutical company publicly traded in India, CNBC TV18 reported Tuesday, citing sources.Zydus may buy a controlling stake in Waltham, Massachusetts-based Ardelyx ( ARDX ) or acquire certain assets and is raising funds via a qualified institutional placement, the report said.Ardelyx ( ARDX ) and Zydus didn't immediately respond to requests for comment from MT Newswires.Ardelyx ( ARDX ) shares rose 13% in Tuesday trading.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: 7.63, Change: +0.88, Percent Change: +12.96 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

醫療業 ETF - Vanguard

納斯達克生物科技指數 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

IBBQ

HIND

RSLS

標普生物技術 3 倍做空 - Direxion

標普生物技術 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

GLSI

根據 CNBC TV18 的報道，Ardelyx（ARDX）可能會被印度一家上市制藥公司 Zydus Life 收購。Zydus reportedly 正在尋求收購 Ardelyx 的控股權或某些資產，並通過合格機構配售籌集資金。Ardelyx 的股價在消息發佈後上漲了 13%。兩家公司均未對此發表評論

市場傳聞：Ardelyx 可能會被 Zydus Life 收購